Thalamus Biosciences

Book a 30-minute call

PD Biomarker and Target-Engagement Plan

We write a biomarker plan that runs from target engagement through pathway pharmacodynamics to disease biomarkers, with the assays, the sample matrices and the validation plan for each.

Decision it supports. Which biomarker assays will inform the first-in-human decision.

For

A program between lead optimization and its first-in-human decision that needs an in vitro and ex vivo PD assay plan.

Scope

One program and its in vitro and ex vivo assays. The clinical team makes the first-in-human decision, and the plan provides the assay information for it.

Inputs

The mechanism and target, the candidate's exposure profile, the indication and the clinical plan, any existing biomarker data, and the CRO or central lab that the program expects to use.

Deliverable

The PD Biomarker Plan, which contains:

  • a biomarker hypothesis map covering proximal target engagement, pathway pharmacodynamics and disease biomarkers
  • a list of assays with the matrix for each one (whole blood, PBMC, plasma or CSF)
  • receptor-occupancy and phospho-flow designs
  • an ex vivo whole-blood stimulation design for PK/PD modeling
  • a fit-for-purpose validation plan covering precision, stability and donor variability
  • sample logistics and the handoff to the CRO
Timeline

Two to three weeks, with a kickoff, one working session and a readout call.

Excluded

The plan does not include running assays, qualifying a central lab, the first-in-human decision itself, clinical operations or CMC.

Immunology and translationalNeuroimmunology and glia

Book a 30-minute call You answer a few short questions and choose a time. On the call we discuss your work and the decision you need to make.